In this episode of "The Top Line," Fierce's Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients.

To learn more about the topics in this episode: 
With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug
Eisai launches 'digital business' Theoria to build out a dementia ecosystem for patients

In this episode of "The Top Line," Fierce's Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients.
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/full-approval-hand-eisai-and-biogen-kick-leqembis-alzheimers-launch-earnest">With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest</a></li>
<li><a href="https://www.fiercepharma.com/pharma/after-winning-full-fda-nod-leqembi-eisai-touts-promising-data-subcutaneous-version">After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version</a></li>
<li><a href="https://www.fiercepharma.com/pharma/eisai-biogens-leqembi-may-face-rollout-hurdles-now-experts-still-alzheimers-drug">Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug</a></li>
<li><a href="https://www.fiercepharma.com/marketing/eisai-launches-digital-business-theoria-build-out-dementia-ecosystem-patients">Eisai launches 'digital business' Theoria to build out a dementia ecosystem for patients</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement